Garner Bio’s Post

Ananda Developments Plc  chairman Charles Morgan described as "profound" the preclinical data generated by its lead asset in an area of cardiology with a high unmet medical need. CBD-derived MRX1, currently also undergoing Phase II trials for chemotherapy-induced peripheral neuropathy and endometriosis, was assessed for its potential in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF). Research conducted by Dr Nadine Godsman and Dr Sarah Walsh at Robert Gordon University (RGU), under the guidance of Professor Cherry Wainwright, a member of Ananda’s scientific advisory board, showed promising results. The study involved male mice divided into two groups: one fed a high-fat diet with L-NAME, a substance used to induce heart stress mimicking HFpEF, and a control group on a normal diet. MRX1 or a modified version was administered orally during the last two weeks of the seven-week study.... More at #Proactive #ProactiveInvestors http://ow.ly/6cCt105ye1u

Exciting News! Our Sclerostin ELISA Assay Kit, from Biomedica Immunoassays, played a crucial role in a recent study that assessed the associations between serum and bone sclerostin levels and biomarkers of bone turnover and bone histomorphometry ! Key Findings: 🔹 Serum sclerostin levels exhibited elevation across both early and late CKD stages. 🔹 Elevated levels of sclerostin, both in circulation and within bone tissue, correlated strongly with markers of bone turnover and mineralization. 🔹 Immunofluorescence analyses revealed a fascinating interplay between sclerostin and the Wnt signaling pathway, shedding light on novel mechanistic insights. #research #sclerostin #eaglebio

I’m thrilled to finally have this study published – available with open access! 😀   We introduce a porcine model of ischemic stroke, using intracortical recordings for continuously tracking the progression of a focal infarction introduced by injection of endothelin-1 (ET-1). The purpose is to develop a model for screening of neuroprotective agents in the hyperacute phase of stroke, which would be simple to expand to a porcine preclinical model and could enhance translation into clinical studies.   It is an example of how things don’t always go exactly to plan in research, especially when you try to implement a lot of new procedures in a complex study. In this study, we had some issues with ET-1 not inducing the stroke in the way we had anticipated beforehand, which made it hard to write up and publish. Even so, I believe the model has great potential given the suggested improvements, and it is certainly one aspect of my old job that I would have loved to follow up on. Even though this model represents a tiny piece of the puzzle, neuroprotective agents holds an enormous untapped potential for future stroke patients!   A big thank you goes out to Winnie Jensen for taking the task of corresponding author and the requested rewriting upon herself!

🆕 A new drug shows potential benefits in the recovery of patients after a heart attack   Researchers from Grup ICREC at Germans Trias i Pujol Research Institute (IGTP) and the Heart Institute of Hospital Universitari Germans Trias i Pujol (iCor) have evaluated the effects of early administration of Sacubitril/Valsartan in a preclinical porcine model of myocardial infarction and found beneficial effects in the management of this condition.   💬 Felipe Bisbal and Carolina Gálvez-Montón, lead authors of the study, say that "the effects of Sacubitril/Valsartan in the porcine model of myocardial infarction are very promising and suggest that this novel drug could substantially improve the prognosis and quality of life of patients who suffer from this event".   Video -in Catalan- where Julia Aranyo and Daina Martínez Falguera explain this research: https://lnkd.in/dF4T-McM Read more: https://lnkd.in/dtVvpaFi #Research #PreclinicalResearch #DrugResearch #MyocardialInfarction #HeartAttack

Can timely targeting and selective removal of elevated NETs from the blood during an acute episode of ischemic stroke, minimize necrotic cell death and tissue infarct size? The preclinical work of Pena-Martinez et. al. suggests hyperactivated NETs are strong potential targets for minimizing experimental ischemic tissue injury to many organs not just the brain. "Delayed Administration of DNase-I Improves Stroke Outcome After Thromboembolic MCAO Despite Lack of Reperfusion" Pena-Martinez et. al 2022 https://lnkd.in/eNNHVnUz

iPSC differentiation and its role in providing patient-specific platforms for drug testing is ushering in an exciting new area of drug discovery and development. The recently enacted FDA Modernization Act 2.0 encourages alternative approaches, including using induced pluripotent stem cells (iPSCs). Human iPSCs provide a patient-specific, precise, and screenable platform for drug testing. https://lnkd.in/esH83uh

All the best to Exact Sciences as they get going into MCEDs via liquid biopsy. The study design to assess the real world utility of liquid biopsy based screening is so important to understand and really think it is focused on what it can bring for patients. The fact that they will embark on this study seems to suggest they have something good with a new assay. Looking forward to these results over the next few years! https://lnkd.in/gddQxcWC

The Muscular Dystrophy Association announced today an MDA Research Infrastructure Grant for $300,000 to Joshua Burns, PhD towards establishing a global certification standard for clinical evaluators focused on Charcot-Marie-Tooth disease (CMT), with the potential to revolutionize the field of muscle disease research. Through collaboration with his team of multinational co-investigators and collaborators, CMT Master Trainers and Patient Advocacy Groups worldwide, Dr. Burns aims to enhance trial readiness and scale-up trial capacity by building a network of reliable evaluators equipped with standardized clinical outcome measures via https://lnkd.in/esKa5xnG, a website established with an MDA Ideas Grant. "The establishment of a global certification standard for evaluating CMT represents a major advance in our ability to translate promising therapies from preclinical development to clinical trials. By ensuring the accuracy and reliability of clinical outcome measures, this initiative has the potential to expedite the translation of research into practice and improve outcomes for people living with CMT and related neuropathies," said Dr. Burns. #MDA #Research #CharcotMarieTooth #CMT #Neuromuscular Read more ⬇ ⬇ ⬇

This paper was presented at ESC Congress 2024; September 2, 2024; London, England. In this lesion-level analysis of the PACMAN-AMI trial, alirocumab treatment in addition to high-intensity statin therapy induced a more extensive atheroma burden reduction, ie, greater than that described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with a greater enlargement of the lesion minimum lumen area (MLA), similar negative arterial remodeling, and a more frequent reclassification of high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes at follow-up.

A recent study by The Journal of Clinical and Translational Research (JCTR) shared the insights of a TruGraf 6-month surveillance biopsy that included several kidney transplant patients. What was discovered from the patients? Dive into the full details here: https://loom.ly/tpF9yAU #KidneyTransplantation #ObservationalStudy